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Abstract 
The objective of this study is to determine the antigen presentation ability of a DNA vaccine model 
that is co-delivered with that of recombinant Salmonella enterica serovar Typhimurium (STM1) expressing 
chemokine macrophage chemotactic protein-3 (MCP-3). The DNA vaccine, pVROVA, was constructed by 
amplification of the ovalbumin coding region from sOVA-C1. Dendritic cells (DCs) were obtained from IL-4 
and GMCSF stimulated mouse bone marrow stem cell. Cultured DCs were incubated with STM1 carrying a 
model ovalbumin gene (pVROVA). Furthermore, MHC class I antigen presentation of a dominant OVA peptide 
was assayed in vitro. The experiments were designed to determine the effect of co-delivering MCP-3 with that 
of ovalbumin in STM1. Our results show that a plasmid pROVA-carrying ovalbumin gene was succesfully 
constructed and sequence analysis of the ovalbumin-coding revealed an identity match of 100% with that of 
the chicken ovalbumin DNA sequences from the GenBank database.  We also found that the presence of the 
MCP-3 encoding plasmid in STM1 or E. coli DH1 could increase the recovery of both STM1 and E. coli DH1 
over those that carry the empty plasmids.  Antigen presentation assay also indicates that MCP-3 can positively 
influence the presentation of ovalbumin. Conclusion: the infection of DCs by STM1-carrying DNA vaccine 
and MCP-3 results in an increase of processing and presentation of ovalbumin in vitro.
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(Wick, 2002). Moreover, Salmonella-infected DCs 
that were not fixed in paraformaldehyde, could 
present foreign epitopes to T cell hybridoma as 
shown by the secretion of IL-2 from the T cell 
(Yrlid et al., 2001, Yrlid and Wick, 2000).  This 
mode of presentation occurs when the bacteria 
does not induce cell death in the infected cells 
(Sundquist et al., 2004). However, Salmonella can 
be cytotoxic, thereby inducing apoptosis to the 
infected cells. In the indirect (cross-presentation) 
method of antigen presentation, bystander DCs 
could phagocytosise any infected or apoptotic 
cells to subsequently obtain and present the 
STM1-related antigens with the assistance 
of MHC class I molecules. In this case, the 
neighboring DCs may internalize apoptotic 
materials and cross-present Salmonella antigens 
to the T cells (Yrlid et al., 2001, Yrlid and Wick, 
2000).  Heat-shock proteins have been proposed 
to be involved in antigen presentation through 
Introduction1
Salmonella enterica serovar Typhimurium 
(STM-1) could infect dendritic cells (DCs) and 
stimulate these cells to present heterologous 
antigens. However, it is not yet known whether 
the DCs antigen presentation is a direct or indirect 
phenomenon. In a direct antigen presentation, 
STM1 is presumably internally ingested into the 
DCs and its peptide directly presented by the 
DCs themselves. Previous study have reported 
that DCs can process Salmonella and directly 
present peptides derived from Salmonella-
encoded antigens to CD4+ and CD8+ T cells 
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the indirect, cross presentation pathway. This 
occurs as antigen presenting cells (APCs) 
take up peptides that are chaperoned by heat 
shock protein released upon cell death (Li et 
al., 2002). APCs then re-present these peptides 
with their MHC molecules (Li et al., 2002). 
It was previously found that intact protein, 
small peptide, or peptide-heat shock proteins 
complexes are essential for cross presenting 
presentation (Shen and Rock, 2004). Despite 
this knowledge however, the exact mechanism 
of antigen transfer from parenchymal cells and 
cross-presentation in vivo remains unclear and 
controversial. 
Murine chemotactic protein, MCP3, 
activates a variety of inflamatory cells through 
a number of different receptors for C-C 
chemokines that are expressed on the target 
cells. This chemokine is a pluripotent CC 
chemokine, which is active on a spectrum 
of cells including monocytes, lymphocytes, 
granulocytes, natural killer (NK) and dendritic 
cells (DCs). MCP was shown to bind to at least 
three different receptors (CCR1, CCR2 and 
CCR3) that are present at these inflammatory 
cells (Wetzel et al., 2001). The biological 
properties of MCP3 offer possibilities for its use 
as an immunotherapy and adjuvant. Previous 
studies have found that the transduction of 
human MCP3 by a parvoral vector induces 
leucocyte infiltration and reduces growth of 
human cervical carcinoma cell xenografted into 
mice.  Interestingly, the DCs, which are among 
the most potent antigen presenting cells, were 
also found to be attracted into MCP3-tranduced 
tumors (Wetzel et al., 2001). MCP3 has also been 
utilized as a genetic adjuvant when it was fused 
with a DNA vaccine and resulted in a broad 
immune response in mice (Biragyn et al., 2002, 
Rainczuk et al., 2003a, Rainczuk et al., 2003b). 
To investigate whether STM1-infected 
DCs present STM1 antigen via direct 
presentation or through cross-presentation, 
an antigen cross-presentation assay using 
DCs with mismatched MHC I haplotypes was 
performed. In this experiment, we could also 
engineer a better immune response against a 
DNA vaccine that is delivered by STM1.  We 
performed this with a DNA vaccine construct, 
pVROVA (encoding ovalbumin), which was 
co-delivered with recombinant MCP-3 in STM1. 
STM1 expressing MCP-3 was used in a variety 
of in vitro experiments to determine the effects 
of the chemokine on the immunogenicity of the 
passenger antigen.  
As the pMOMCP-3 and pVROVA 
plasmids confer ampicillin and kanamycin 
resistance, respectively, it was possible to 
use drugs selection method in ensuring that 
both plasmids were retained during culture. 
The pVROVA DNA vaccine plasmid will be 
express ovalbumin only in eukaryotic cells, and 
can only occur if there is a transfer of the DNA 
vaccine to the cell nucleus. The use of MCP-3 
molecule as an immunological adjuvant might 
be applied to any bacterial vaccine delivery 
strain. Furthermore, because S. Typhimurium 
is invasive in mice, an initial concern would be 
that MCP-3 may only exert its effect due to this 
invasive property of S. Typhimurium itself.  To 
investigate this, we thus utilised a non-invasive 
E. coli DH1 that might reveal the ability of MCP-
3 to augment the immunogenicity of bacteria 
that are normally non-invasive.  
Materials and Methods
Plasmids and bacterial strain used in this 
study 
Plasmids, bacterial strains and cell 
lines used in these experiments are listed in 
Table 1.
DNA vaccine construction
We have constructed a DNA vaccine 
encoding ovalbumin that was encoded by 
a plasmid selected for ampicillin resistance 
(Rainczuk et al., 2003a). It was necessary to 
re-clone the ovalbumin coding sequence 
into a vector with a different drug resistance 
marker, to enable dual selection with the 
MCP-3 encoding plasmid.  The DNA vaccine, 
pVROVA, was constructed by amplification 
of the ovalbumin coding region from sOVA-
C1 (Figure 1) with primers (5’CGCGGATC
CATGGGCTCCATCGGTGCAGC3’) and 
(5’CGCGGATCC TTAAGGGGAAACACA
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TCTGCC3’). 
                       
  
Figure 1. Plasmid map of the eukaryotic expression 
vector, sOVA-C1, which contains the ovalbumin (OVA) 
gene and ampicillin (Amp) resistance gene. 
The PCR product was digested with 
BamHI (sites underlined) and inserted into 
pVR1012 (Figure 2) that had been digested 
with the same enzyme. 
The resultant plasmid, pVROVA (Figure 
3) carries a CMV promoter that could direct 
ovalbumin expression into the cytoplasmic 
compartment of mammalian cells. 
Bacteria were transformed with plasmid 
DNA as previously described (Bachtiar et al., 
2003). The plasmid was first transformed 
into LT2-9121, and plasmid DNA was 
subsequently isolated from this strain prior 
to electroporation into STM1. Passaging of 
Table 1 Plasmids, bacterial strains and cell line  used in this experiment 
Bacterial strains and cell lines Features, use, source
E. coli DH5α
E. coli DH1
S. Typhimurium LT2-9121
S. Typhimurium, STM1
B3Z86/90.14
Maintenance of plasmid DNA (Hanahan, 1983).
Vaccination of mice (Hanahan, 1983).
Passage plasmid DNA (Reeves and Stevenson, 1989)
Attenuated vaccine strain (aroA-).  Used for the vaccination of 
mice (Alderton et al., 1991)
T cell hybridoma restricted to CD8+ H2Kb OVA peptide SIINFEKL 
Plasmids
pMOhly1
pMOMCP-3  
pVR1012
pVROVA
Ampr, prokaryotic expression vector with haemolysin secretor 
signal apparatus (Spreng et al., 1999)
pMOhly1 expressing MCP-3. (this study)
Kanr, CMV promoter (DNA vaccine). VICAL Inc, USA
pVR1012 expressing chicken ovalbumin. (this study)
sOVA-C1
5301 bps
1000
2000
3000
4000
5000
BsrGI
SpeI
SnaBI
HindIII
BspMI
XhoI
EcoRI
XcmI
Bst1107I
PvuII
StuI
BtrI
AflIII
SapI
BbvCI
Bpu10I
EcoRV
XbaI
SalI
SmaI
XmaI
NotI
Eco52I
HpaI
MunI
ClaI
BamHI
PvuI
DraIII
PvuI
AhdI
BglII
OVA
Amp
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Figure 2. Plasmid pVR1012 harbouring the kanamycin resistance gene and CMV 
promoter.  
 
The resultant plasmid, pVROVA (Figure 3) carries a CMV promoter that could direct 
ovalbumin expression into the cytoplasmic compartment of mammalian cells.  
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Figure 2. Plasmid pVR1012 harbouring the kanamycin 
resistance gene and CMV promoter.
Figure 3. A schematic representative of pROVA, a 
VR1012 based DNA vaccine harbouring the chicken 
ovalbumin gene.
plasmid DNA via LT2-9121 ensures stability 
of plasmid DNA in STM1. 
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Sequence analysis of pVROVA 
To ensure the new clone pVROVA 
is bearing an ovalbumin coding-DNA 
sequence, VROVA was subjected to DNA 
sequencing using either the forward primer 
(5’CG GATCCATGGGCTCCATCGGTGCA
GC3’) or reverse primer (5’CGCGGATCCTT 
AGGGAAACACATCTGCC3’), using the Big 
Dye termination kit. 
Antigen presentation assay
Six to eight week old female C57BL/6 
(H2Kb) and Balb/C (H2Kd) SPF mice were used 
in these experiments. Mice were obtained from 
the Animal Resource Centre, Perth, Australia 
and were housed at RMIT University animal 
facility, Melbourne Australia. Animal ethic 
experiment was approved by RMIT University 
Ethic Comission. Denditic cells were obtained 
from mouse femura bone marrow after 
incubation with GMCSF and IL-4 (Rainczuk 
et al., 2003b). The ability of mammalian cells 
infected with STM1 carrying the ovalbumin-
expressing plasmid pVROVA to stimulate B3Z 
cells (B3Z cells are a murine T cell hybridoma 
specic for the dominant H2Kb MHC class 
I/ovalbumin epitope 257-264, of sequence 
SIINFEKL) was assessed.  To do this, DCs 
were cultured and incubated with STM1 
carrying pVROVA and MHC class 1 antigen 
presentation of a dominant OVA peptide was 
assayed as previously described in (Bachtiar 
et al., 2003). A cross-presentation assay was 
performed as follows. DCs with a B3Z cells-
mismatched haplotype (i.e; H2Kd) were set 
to ingest STM1. We then add the cells with 
a B3Z cells-matched haplotype to determine 
(using appropriate control groups) whether 
the DCs directly present the OVA peptide 
or if it does so through a cross-presentation 
pathway. In order to determine this, DCs of 
the first haplotype were incubated with STM1 
for one hour. Antibiotic was then added to kill 
any extracellular STM1, and the second aliquot 
of DCs (of either matched or mismatched 
haplotype) was added. As all extracellular 
bacteria were killed prior to the addition of 
the second aliquot of DCs, they could only 
access STM1 antigen from the first batch of DCs 
that have taken up STM1.  The cultures were 
incubated overnight, and B3Z cells were added. 
For quantification of antigen presentation, 
the same colorimetric assay as described in 
(Bachtiar et al., 2003) was performed the next 
day.  Therefore, any presentation of OVA 
peptide by the second aliquot of DCs added 
was presumed to be by cross-presentation. 
Figure 4 summarises the three repetitions of 
this experiment. 
In vitro uptake of E. coli DH1 by cultured 
DCs
To evaluate the effect of Macrophages 
Chemotactic Protein, MCP-3 on the uptake of 
E. coli DH1 by cultured DCs,  we incubated 
either E. coli alone, E. coli with empty plasmid 
and E. coli carrying MCP-3 encoding DNA 
together with the DCs at infection multiplicity 
of 100 as was previously conducted with 
STM1 (Bachtiar et al., 2003). The percentage 
uptake of bacterial cells (compared to the 
original inoculum) was analysed by T test.
Results
Construction of the pVROVA DNA vaccine
The chicken ovalbumin gene was 
successfully cloned into the pVR1012 vector 
and digestion using BamH1 (the cloning 
sites) confirmed the resultant positive clones; 
(lanes 2 and 15) consist of a 1.3 kb DNA 
fragment (Figure 5). 
Figure 4. Schematic diagram of the cross-presentation 
assay
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Figure 4.  Schematic diagram of the cross-presentation assay 
 In vitro uptake of E. coli DH1 by cultured DCs 
To evaluate the effect of Macrophages Chemotactic Protein, MCP-3 on the uptake of E.
coli DH1 by cultured DCs,  we incubated either E. coli alone, E. coli with empty plasmid 
and E. coli carrying MCP-3 encoding DNA together with the DCs at infection 
multiplicity of 100 as was previously conducted with STM1 (Bachtiar).  The percentage 
uptake of bacterial cells (compared to the original inoculum) was analysed by T test. 
 
Results
Construction of the pVROVA DNA vaccine 
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Figure 6.  Uptake of E. coli DH1 (A) and STM1 (B) with and without MCP-3-expressing plasmid 
by cultured DCs.  P values: DH1 vs. EV/DH1 (P < 0.05); MCP-3/DH1 vs. DH1 (p >0.05); MCP-
3/DH1 vs. EV/DH1 (P <0.05); MCP-3/STM1 vs. STM1 (P < 0.01); MCP-3/STM1vs. EV/STM1, 
(P < 0.05).  Note data of STM1 experiment was taken from previous experiment (see section 
4.3.3). EV: Empty vector (pMOHly1). Figure 6 C. In vitro signalling of T cells by incubated 
with STM1 DCs STM1 was transformed with either empty plasmid (VR1012/STM1); 
MCP-3/STM1; DNA vaccine alone (VROVA/STM1) or DNA vaccine and chemokine 
(VROVA/MCP-3/STM1). STM1 was then incubated with cultured DCs. The signalling 
of B3Z cells was measured in colorimetric assay. Only those carrying VROVA should 
signal. Values obtained from OVA expressing plasmid with MCP-3 were compared with 
those without MCP-3. VROVA/MCP-3/STM1 vs. VROVA/EV/STM1, P<0.005; 
VROVA/MCP-3/STM1 vs. VROVA/STM1, P < 0.05; VROVA/MCP-3/STM1 vs. MCP-
3/STM1, P < 0.001. EV: Empty vector (pMOhly1).  
 
This shows that the presence of the MCP-3 encoding plasmid in STM1 or E. coli DH1 
could increase the recovery of both STM1 and E. coli DH1 over those that carry the 
empty plasmids. 
 
Antigen presentation and cross-presentation analysis 
In addition to the plasmid directing MCP-3 expression, a second plasmid encoding 
ovalbumin (pVROVA) was introduced into STM1.  As pMOMCP-3 and pVROVA 
plasmids confer ampicillin and kanamycin resistance respectively, using drug selection 
enabled both plasmids to be retained in STM1.  The existence of plasmids in STM1 was 
Figure 6.  Uptake of E. coli DH1 (A) and STM1 (B) with and without MCP-3-expressing plasmid by cultured DCs. 
P values: DH1 vs. EV/DH1 (P < 0.05); MCP-3/DH1 vs. DH1 (p >0.05); MCP-3/DH1 vs. EV/DH1 (P <0.05); MCP-
3/STM1 vs. STM1 (P < 0.01); MCP-3/STM1vs. EV/STM1, (P < 0.05).  Note data of STM1 experiment was taken from 
previous experiment (see section 4.3.3). EV: Empty vector (pMOHly1). Figure 6 C. In vitro signalling of T cells by 
incubated with STM1 DCs STM1 was transformed with either empty plasmid (VR1012/STM1); MCP-3/STM1; DNA 
vaccine alone (VROVA/STM1) or DNA vaccine and chemokine (VROVA/MCP-3/STM1). STM1 was then incubated 
with cultured DCs. The signalling of B3Z cells was measured in colorimetric assay. Only those carrying VROVA 
should signal. Values obtained from OVA expressing plasmid with MCP-3 were compared with those without 
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Sequence analysis of the ovalbumin-
coding region in clone 15 revealed an identity 
match of 100% with that of the chicken 
ovalbumin DNA sequences from the GenBank 
database. This clone was termed pVROVA and 
was used for subsequent experiments.
 
In vitro uptake of STM1 and E. coli by 
cultured DCs.
As a simple indicator of the effectiveness 
of secreted MCP-3 to promote uptake by DCs, 
the bacterium with and without MCP-3 
encoding plasmid was incubated with murine 
bone-marrow cells that had been enriched for 
DCs with GMCSF and IL-4. Results for E.
Figure 5.  DNA gel electrophoresis of potential pVROVA clones.  Lane 1 and lane 11, λ/PstI.  Restriction enzyme 
BamH1 was used to digest plasmid DNA.  Successful clones with two bands; 4.3 kb (pVR1012) and 1.3 kb (ovalbumin-
coding sequence) were observed in lane 2 and lane 15.  
coli are shown in Figure 6 compared to those 
previously obtained for STM1.  
This shows that the presence of the 
MCP-3 encoding plasmid in STM1 or E. coli 
DH1 could increase the recovery of both STM1 
and E. coli DH1 over those that carry the empty 
plasmids. 
Antigen presentation and cross-presentation 
analysis
In addition to the plasmid directing 
MCP-3 expression, a second plasmid encoding 
ovalbumin (pVROVA) was introduced into 
STM1. As pMOMCP-3 and pVROVA plasmids 
confer ampicillin and kanamycin resistance 
   1     2    3     4    5      6    7    8    9   10     11   12   13    14  15  16   17  18   19   20
4.3 kb
1.3 kb
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respectively, using drug selection enabled 
both plasmids to be retained in STM1. The 
existence of plasmids in STM1 was confirmed 
by PCR amplification with the appropriate 
primers (i.e. MCP-3 and ovalbumin primers) 
as described in (Bachtiar, 2005).  It was found 
that under drug selection with ampicillin and 
kanamycin both plasmids were maintained. 
Plasmid VROVA will direct the expression of 
ovalbumin only in eukaryotic cells, and can 
therefore only occur if there is (1) uptake of 
STM1 by eukaryotic cells and (2) transfer of the 
DNA vaccine to the nucleus. These processes 
were monitored by analysing the presentation 
of the dominant CD8+ epitope of ovalbumin, 
SIINFEKL, to T cells as previously described 
in (Bachtiar et al., 2003). Figure 6 B shows that 
maximal stimulation of the reporter CTL cell 
line B3Z86/90 was obtained after incubation 
with STM1 carrying the MCP-3-expressing 
plasmid (more than three-fold increase over 
STM1 carrying the empty vector, P < 0.05), 
indicating  that MCP-3 positively influenced 
the presentation of ovalbumin.
A cross presentation analysis indicated 
that DCs might predominantly involve in a 
direct presentation of the ovalbumin peptide 
rather than cross-presentation to T cell (Figure 
6C). Firstly, the group of which only Balb/C 
DCs were added showed that this haplotype 
cannot present.  When Balb/C are added first, 
followed by C57BL/6 (after elimination of 
extracellular bacteria), there is only a relatively 
minor increase in presentation. This is probably 
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Figure 7. MHC class I presentation to dominant ovalbumin CD8+ epitope by DCs to B3Z 
T cell. Data from 2 independent experiments is shown (A and B). The assay was 
performed by sequential co-culture of DCs with a matched or mismatched haplotype to 
B3Z cells. STM1 carrying the indicated plasmid constructs was incubated with DCs from 
either Balb/C or C57BL/6 mice. After 1 h incubation and killing of the extracellular 
bacteria, each infected-DC culture was co-cultured with matched or mismatched DCs 
(C57-C57; C57-Balb/C; Balb/C-Balb/C or Balb/C-C57) followed by addition the 
responder cell (B3Z cells). The signalling of responder cells was then measured.  
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specific; however, as in the first experiment 
(Figure 7A and Figure 7B) the only increase was 
seen in cells that carried OVA sequences.  
In the second experiment, this increase 
was only seen in the VROVA/MCP-3/STM1 
group. Conversely, when C57BL/6 cells were 
added first, followed by either an aliquot of 
C57BL/6 or Balb/C presentation was at a 
high level.  
Finally, this experiment demonstrates 
a positive effect of the presence of MCP-3 
to the magnitude of antigen presentation of 
SIINFEKL by DCs to T cells, as DCs incubated 
with STM1 expressing this chemokine 
increased antigen presentation over that of 
STM1 with the empty vector (P<0.05). 
Discussion
The ability of APCs surveying the gut 
mucosa to take up S. Typhimurium is one 
requirement for efficient oral STM1-based 
DNA vaccination. Activated APCs migrate to 
the lymph nodes, then produce and process 
the passenger molecule for further presentation 
to immune cells. The results revealed that 
the signalling of B3Z cells (T cells receptors 
recognising MHC class I/SIINFEKL) could 
increase ovalbumin expressing plasmid with 
MCP-3 over those without MCP-3.  It indicated 
that in vitro, co-delivery of a DNA vaccine with 
a chemoattractant molecule MCP-3, enhanced 
the ability of cultured DCs to take up, process 
and present passenger antigens carried by 
STM1. This finding supports the previous study 
that MCP-3 increased the immunogenicity of 
STM1 (Bachtiar, 2005), it is probable that 
increased antigen presentation might be due 
to increased uptake of MCP-3-secreting STM1 
(Bachtiar et al., 2003). In future experiments, 
trafficking of DCs to MCP-3-secreting STM1 
shall be investigated.
Infection of bone marrow-derived 
macrophages with wild-type S. Typhimurium 
14028 results in presentation of epitopes 
derived from a bacterial encoded antigen on 
MHC class I (Catic et al., 1999, Svensson and 
Wick, 1999) and MHC class II molecules after 
internalisation of apoptotic macrophages by 
bystander DCs (Yrlid et al., 2000, Svensson et 
al., 1997). In this current study, an experiment 
was designed to determine if the presentation 
of antigen was performed by the APC’s that 
actually take up the bacterial vaccine. The in 
vitro analysis was performed where cultured 
DCs were incubated with STM1 carrying 
a model ovalbumin gene and MHC class 
I antigen presentation of dominant OVA 
peptide was assayed.  It was shown that STM1 
could be taken up by the cells and enable 
heterologous antigen presentation (Bachtiar 
et al., 2003). An assay was performed in order 
to determine if this presentation is direct 
(i.e. the DCs that take up the STM1 present 
the peptide), or indirect (cross-presentation) 
where bystander DCs phagocytose infected 
cells and subsequently present the peptide by 
cross-presentation through MHC class I. The 
result from this assay indicated that the mode 
of antigen presentation occurred primarily via 
a direct antigen presentation, with minimal 
contribution of the cross-presentation method. 
In these experiments, the incubation with the 
second aliquot of DCs was done overnight. It 
may be that longer incubation would result in 
an increased of cross-presentation. This study 
suggests the possibility of vaccine development 
by STM1 carrying DNA vaccine and MCP-3.
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